Isidro Cortes Ciriano

Research Group Leader

European Bioinformatics Institute
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (27)

Year:

2026

Year:

2025

Complex de novo structural variants (dnSVs) are crucial genetic factors in rare disorders, yet their prevalence and characteristics in rare disorders remain poorly understood. Here, we conduct a comprehensive analysis of whole-genome sequencing data of 12,568 families, including 13,698 offspring with rare diseases, obtained as part of the UK 100,000 Genomes Project. We identify 1,870 dnSVs, constituting the largest dnSV dataset reported to date. Complex dnSVs (n = 158; 8.4%) emerge as the third most common type of SV, following simple deletions and duplications. We classify 65% of these complex dnSVs into 11 subtypes. Among probands with dnSVs (n = 1,696), 9% exhibit exon-disrupting pathogenic dnSVs associated with the probands’ phenotype. Notably, 12% of exon-disrupting pathogenic dnSVs and 22% of de novo deletions or duplications previously identified by array-based or whole-exome sequencing methods are found to be complex dnSVs. We also find distinct genomic properties of de novo deletions depending on the parent of origin. This study highlights the importance of complex dnSVs in the cause of rare disorders and demonstrates the necessity of specific genomic analysis to avoid overlooking these variants.

Year:

2025

Supplementary Table 1 includes the metadata on all subjects, including basic demographics and medical history. Supplementary Table 2 provides statistics on chrom 8 gene expression among tumors with H3K27me3 loss. Note: no changes have been made to this file since our last resubmission.

Year:

2025

Somatic chromosome instability results in widespread structural and numerical chromosomal abnormalities (CAs) during cancer evolution 1–3 . Although CAs have been linked to mitotic errors resulting in the emergence of nuclear atypia 4–7 , the underlying processes and rates of spontaneous CA formation in human cells are underexplored. Here we introduce machine-learning-assisted genomics and imaging convergence (MAGIC)—an autonomously operated platform that integrates live-cell imaging of micronucleated cells, machine learning on-the-fly and single-cell genomics to systematically investigate CA formation. Applying MAGIC to near-diploid, non-transformed cell lines, we track de novo CAs over successive cell cycles, highlighting the common role of dicentric chromosomes as initiating events. We determine the baseline CA mutation rate, which approximately doubles in TP53 -deficient cells, and observe that chromosome losses arise more frequently than gains. The targeted induction of DNA double-strand breaks along chromosome arms triggers distinct CA processes, revealing stable isochromosomes, coordinated segregation and amplification of isoacentric segments in multiples of two, as well as complex CA outcomes, influenced by the chromosomal break location. Our data contrast de novo CA spectra from somatic mutational landscapes after selection occurred. The experimentation enabled by MAGIC advances the dissection of DNA rearrangement processes, shedding light on fundamental determinants of chromosomal instability.

Year:

2025

We profiled a large heterogeneous cohort of matched diagnostic relapse tumor tissue and paired plasma-derived cell-free DNA (cfDNA) from patients with relapsed and progressive solid tumors of childhood. Tissue and cfDNA sequencing results were concordant, with a wider spectrum of mutant alleles and higher degree of intratumor heterogeneity captured by the latter, if sufficient ctDNA was present. Serial tumor sequencing identified putative drivers of relapse, with alterations in epigenetic drivers being a common feature. In keeping with epigenetic alterations being a common driver of many childhood cancers, fragmentomic analysis of cfDNA identified tumor-specific epigenetic states and transcription factor binding sites accessible in chromatin. This study leverages a large and well-annotated genomic dataset of aggressive childhood malignancies, identifies genomic and epigenetic drivers of childhood cancer relapse, and highlights the power and practicality of cfDNA analysis to capture both intratumoral heterogeneity and the epigenetic state of cancer cells. Significance: In tumors of childhood, we identify mutations in epigenetic genes as drivers of relapse, with matched cfDNA sequencing showing significant intratumor genetic heterogeneity and cell-state specific patterns of chromatin accessibility. This highlights the power of cfDNA analysis to identify both genetic and epigenetic drivers of aggressive disease in pediatric cancers.

Year:

2025

Year:

2024

Mitotic errors generate micronuclei entrapping mis-segregated chromosomes, which are susceptible to catastrophic fragmentation through chromothripsis. The reassembly of fragmented chromosomes by error-prone DNA double-strand break (DSB) repair generates diverse genomic rearrangements associated with human diseases. How specific repair pathways recognize and process these lesions remains poorly understood. Here we use CRISPR/Cas9 to systematically inactivate distinct DSB repair pathways and interrogate the rearrangement landscape of fragmented chromosomes. Deletion of canonical non-homologous end joining (NHEJ) components substantially reduces complex rearrangements and shifts the rearrangement landscape toward simple alterations without the characteristic patterns of chromothripsis. Following reincorporation into the nucleus, fragmented chromosomes localize within sub-nuclear micronuclei bodies (MN bodies) and undergo ligation by NHEJ within a single cell cycle. In the absence of NHEJ, chromosome fragments are rarely engaged by alternative end-joining or recombination-based mechanisms, resulting in delayed repair kinetics, persistent 53BP1-labeled MN bodies, and cell cycle arrest. Thus, we provide evidence supporting NHEJ as the exclusive DSB repair pathway generating complex rearrangements from mitotic errors.

Year:

2024

Telomere fusions (TFs) can trigger the accumulation of oncogenic alterations leading to malignant transformation and drug resistance. Despite their relevance in tumour evolution, our understanding of the patterns and consequences of TFs in human cancers remains limited. Here, we characterize the rates and spectrum of somatic TFs across >30 cancer types using whole-genome sequencing data. TFs are pervasive in human tumours with rates varying markedly across and within cancer types. In addition to end-to-end fusions, we find patterns of TFs that we mechanistically link to the activity of the alternative lengthening of telomeres (ALT) pathway. We show that TFs can be detected in the blood of cancer patients, which enables cancer detection with high specificity and sensitivity even for early-stage tumours and cancers of high unmet clinical need. Overall, we report a genomic footprint that enables characterization of the telomere maintenance mechanism of tumours and liquid biopsy analysis.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (67)

Raymond H. Kim

Associate Professor

University Health Network

CANADA
View details

Ruoyan Li

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marlies Meisel

Assistant Professor (tenure track)

University of Pittsburgh

UNITED STATES
View details

Jose Espejo Valle-Inclan

Principal Investigator

Champalimaud Foundation

PORTUGAL
View details

Russell Taylor Sundby

Assistant Professor

Thomas Jefferson University

UNITED STATES
View details

Elizabeth Christie

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Sahand Hormoz

Dana-Farber Cancer Institute

UNITED STATES
View details

Raheleh Rahbari

Group Leader

Wellcome Sanger Institute

UNITED KINGDOM
View details

Brendan C. Dickson

-

CANADA
View details

Michael Hubank

Professor of Translational Genomics

University College London

UNITED KINGDOM
View details

Juliet Gray

Professor of Paediatric Oncology

University of Southampton

UNITED KINGDOM
View details

Emanuel Gonçalves

Assistant Professor

Instituto de Engenharia de Sistemas e Computadores Tecnologia e Ciência

PORTUGAL
View details

Matija Snuderl

Assistant Professor (Clinical) of Pathology

NYU School of Medicine

UNITED STATES
View details

Peter Park

Harvard University

UNITED STATES
View details

Adrienne M Flanagan

Professor of Musculoskeletal Pathology

-

UNITED KINGDOM
View details

Chris Jones

Professor of Childhood Brain Tumour Biology

Institute of Cancer Research

UNITED KINGDOM
View details

Justin Jordan

University of Texas Southwestern Medical Center

UNITED STATES
View details

Steven C. Clifford

Prof of Molecular Paediatric Oncology

Newcastle University

UNITED KINGDOM
View details

Kathleen Burns

Professor and Department Chair

Dana-Farber Cancer Institute

UNITED STATES
View details

Jihoon Kim

Assistant Professor

Yale University

UNITED STATES
View details

Susanne Andrea Gatz

University of Birmingham

UNITED KINGDOM
View details

Jeffrey Szymanski

Assistant Professor

Mayo Clinic Minnesota

UNITED STATES
View details

William Anderson

University College London

UNITED KINGDOM
View details

Guy Makin

Senior Lecturer in Paediatric Oncology

The University of Manchester

UNITED KINGDOM
View details

Trevor A Graham

Director

Institute of Cancer Research

UNITED KINGDOM
View details

Janet Shipley

Group Leader, Sarcoma Molecular Pathology

Institute of Cancer Research

UNITED KINGDOM
View details

David Viskochil

Professor

University of Utah

UNITED STATES
View details

Deborah A. Tweddle

-

UNITED KINGDOM
View details

Joseph Christopher

University of Cambridge

UNITED KINGDOM
View details

Abel Gonzalez-Perez

Co-PI

IRB Barcelona

SPAIN
View details

Ridwan Shaikh

Institute of Cancer Research

UNITED KINGDOM
View details

Pedro Beltrao

Associate Professor

ETH Zürich

SWITZERLAND
View details

Edward Curry

Imperial College London

UNITED KINGDOM
View details

Bissan Al-Lazikani

Professor, Director of Therapeutics Data Science

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rita Cascão

Gulbenkian Institute for Molecular Medicine

PORTUGAL
View details

Chong Chu

Principal Investigator

The Wistar Institute

UNITED STATES
View details

Francisco Sanchez-Vega

Assistant Attending Computational Biologist

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Carlos Caldas

Professor

Hebrew University of Jerusalem

ISRAEL
View details

Angela C. Hirbe

Washington University School of Medicine

UNITED STATES
View details

Sally George

Institute of Cancer Research

UNITED KINGDOM
View details

Matthew Hurles

Wellcome Sanger Institute

UNITED KINGDOM
View details

Anthony Davis

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Nischalan Pillay

Professor

University College London

UNITED KINGDOM
View details

Maxime Tarabichi

Group Leader

Université libre de Bruxelles

BELGIUM
View details

Alicia L Bruzos

Junior Group Leader of Marine Transmissible Cancers Group

Max Planck Institute for Marine Microbiology

GERMANY
View details

Peter Campbell

Wellcome Sanger Institute

UNITED KINGDOM
View details

Elsa Bernard

Group Leader

Institut Gustave Roussy

FRANCE
View details

Richard Grundy

Professor of Paediatric Neuro-Oncology and Cancer Biology

University of Nottingham

UNITED KINGDOM
View details

Kevin Jones

Professor

University of Utah

UNITED STATES
View details

Peter Ly

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Ofer Shoshani

Assistant Prof

Weizmann Institute of Science

ISRAEL
View details

Louis Chesler

professor

Institute of Cancer Research

UNITED KINGDOM
View details

Claudia Faria

Invited Assistant Professor

Universidade do Porto Faculdade de Medicina

PORTUGAL
View details

Marta Kovatcheva

Group Leader (Assistant Professor Equivalent)

IFOM – The AIRC Institute of Molecular Oncology

ITALY
View details

Amos Burke

Professor of Paediatric Oncology and Director

University of Birmingham

UNITED KINGDOM
View details

Nathan Reticker-Flynn

Assistant Professor

Stanford University

UNITED STATES
View details

Andrea Sottoriva

Head

Human Technopole

ITALY
View details

Yoshihiro Nishida

Nagoya University Hospital

JAPAN
View details

Peter Westcott

Assistant Professor

Massachusetts Institute of Technology

UNITED STATES
View details

Ken Chen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Samantha Bersani

University of Verona

ITALY
View details

Marilyn Bui

Senior Member and Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Darren Hargrave

University College London

UNITED KINGDOM
View details

Anke Katharina Bergmann

Director, Chair

University Hospital Würzburg

GERMANY
View details

Carolin Sauer

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details

Pamela Kearns

University of Birmingham

UNITED KINGDOM
View details

Aylwyn Scally

Group leader

University of Cambridge

UNITED KINGDOM
View details